New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Syndax Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Syndax Pharmaceuticals, Inc.

Oct-03	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) SNDX GlobeNewswire
Sep-19	Syndax's Revuforj (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia SNDX GlobeNewswire
Sep-05	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) SNDX GlobeNewswire
Aug-26	Syndax Announces Participation in September Investor Conferences SNDX GlobeNewswire
Aug-06	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) SNDX GlobeNewswire
Aug-04	Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update SNDX GlobeNewswire
Jul-28	Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025 SNDX GlobeNewswire
Jul-02	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) SNDX GlobeNewswire
Jun-24	Syndax Announces FDA Priority Review of sNDA for Revuforj (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia SNDX GlobeNewswire
Jun-12	Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025 SNDX GlobeNewswire
Jun-12	Syndax Presents New Revuforj (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025 SNDX GlobeNewswire
Jun-05	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) SNDX GlobeNewswire
May-29	Syndax Announces Participation in June Investor Conferences SNDX GlobeNewswire
May-14	Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj (revumenib) and Niktimvo (axatilimab-csfr) SNDX GlobeNewswire
May-12	Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer SNDX GlobeNewswire
May-08	Syndax Announces Participation in May Investor Conferences SNDX GlobeNewswire
May-07	Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood SNDX GlobeNewswire
May-05	Syndax Reports First Quarter 2025 Financial Results and Provides Business Update SNDX GlobeNewswire
May-02	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) SNDX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.